D
David K. Packham
Researcher at University of Melbourne
Publications - 77
Citations - 4262
David K. Packham is an academic researcher from University of Melbourne. The author has contributed to research in topics: Pregnancy & Kidney disease. The author has an hindex of 29, co-authored 75 publications receiving 3750 citations. Previous affiliations of David K. Packham include University of Maryland, Baltimore & Austin Hospital.
Papers
More filters
Journal ArticleDOI
Vitamin D Therapy and Cardiac Structure and Function in Patients With Chronic Kidney Disease: The PRIMO Randomized Controlled Trial
Ravi Thadhani,Evan Appelbaum,Yili Pritchett,Yuchiao Chang,Julia Wenger,Hector Tamez,Ishir Bhan,Rajiv Agarwal,Carmine Zoccali,Christoph Wanner,Donald M. Lloyd-Jones,J.B. Cannata,B. Taylor Thompson,Dennis L. Andress,Wuyan Zhang,David K. Packham,David K. Packham,Bhupinder Singh,Daniel Zehnder,Amil M. Shah,Ajay Pachika,Warren J. Manning,Scott D. Solomon +22 more
Abstract: Context Vitamin D is associated with decreased cardiovascular-related morbidity and mortality, possibly by modifying cardiac structure and function, yet firm evidence for either remains lacking. Objective To determine the effects of an active vitamin D compound, paricalcitol, on left ventricular mass over 48 weeks in patients with an estimated glomerular filtration rate of 15 to 60 mL/min/1.73 m 2 . Design, Setting, and Participants Multinational, double-blind, randomized placebo-controlled trial among 227 patients with chronic kidney disease, mild to moderate left ventricular hypertrophy, and preserved left ventricular ejection fraction, conducted in 11 countries from July 2008 through September 2010. Intervention Participants were randomly assigned to receive oral paricalcitol, 2 μg/d (n =115), or matching placebo (n = 112). Main Outcome Measures Change in left ventricular mass index over 48 weeks by cardiovascular magnetic resonance imaging. Secondary end points included echocardiographic changes in left ventricular diastolic function. Results Treatment with paricalcitol reduced parathyroid hormone levels within 4 weeks and maintained levels within the normal range throughout the study duration. At 48 weeks, the change in left ventricular mass index did not differ between treatment groups (paricalcitol group, 0.34 g/m 2.7 [95% CI, −0.14 to 0.83 g/m 2.7 ] vs placebo group, −0.07 g/m 2.7 [95% CI, −0.55 to 0.42 g/m 2.7 ]). Doppler measures of diastolic function including peak early diastolic lateral mitral annular tissue velocity (paricalcitol group, −0.01 cm/s [95% CI, −0.63 to 0.60 cm/s] vs placebo group, −0.30 cm/s [95% CI, −0.93 to 0.34 cm/s]) also did not differ. Episodes of hypercalcemia were more frequent in the paricalcitol group compared with the placebo group. Conclusion Forty-eight week therapy with paricalcitol did not alter left ventricular mass index or improve certain measures of diastolic dysfunction in patients with chronic kidney disease. Trial Registration clinicaltrials.gov Identifier: NCT00497146
Vitamin D Therapy and Cardiac Structure and Function in Patients With Chronic Kidney Disease
Ravi Thadhani,Evan Appelbaum,Yili Pritchett,Julia Wenger,Hector Tamez,Ishir Bhan,Rajiv Agarwal,Carmine Zoccali,Christoph Wanner,Donald M. Lloyd-Jones,J.B. Cannata,B. Taylor Thompson,Dennis L. Andress,Wuyan Zhang,David K. Packham,Bhupinder Singh,Daniel Zehnder,Amil M. Shah,Warren J. Manning,Scott D. Solomon +19 more
TL;DR: Forty-eight week therapy with paricalcitol did not alter left ventricular mass index or improve certain measures of diastolic dysfunction in patients with chronic kidney disease.
Journal ArticleDOI
Sodium Zirconium Cyclosilicate in Hyperkalemia
David K. Packham,Henrik S. Rasmussen,Philip T. Lavin,Mohamed A. El-Shahawy,Simon D. Roger,Geoffrey A. Block,Wajeh Y. Qunibi,Pablo E. Pergola,Bhupinder Singh +8 more
TL;DR: Patients with hyperkalemia who received ZS-9, as compared with those who received placebo, had a significant reduction in potassium levels at 48 hours, with normokalemia maintained during 12 days of maintenance therapy.
Journal ArticleDOI
Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.
Mikhail Kosiborod,Henrik S. Rasmussen,Philip T. Lavin,Wajeh Y. Qunibi,Bruce Spinowitz,David K. Packham,Simon D. Roger,Alex Yang,Edgar V. Lerma,Bhupinder Singh +9 more
TL;DR: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial evaluating zirconium cyclosilicate in outpatients with hyperkalemia for 28 days, with results indicating that serum potassium levels declined in the open-label phase and was significantly lower in the randomized phase.
Journal ArticleDOI
Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.
David K. Packham,Tahira P. Alves,Jamie P. Dwyer,Robert C. Atkins,Dick de Zeeuw,Mark E. Cooper,Shahnaz Shahinfar,Julia B. Lewis,Hiddo J.L. Heerspink +8 more
TL;DR: Patients with type 2 diabetic nephropathy, characterized by decreased kidney function and significant proteinuria, are more likely to reach ESRD than die during 3 years' mean follow-up, and this has implications for predicting future renal replacement therapy requirements.